

Electronic supplementary material

ESM Table 1 Reasons for premature discontinuation of study drugs in type 2 diabetic patients with overt proteinuria and renal insufficiency randomized to receive either olmesartan or placebo for a mean follow up period of 3.2 years.

Variable	Olmesartan	Placebo
	<i>n</i> (%)	
All patients (Olmesartan = 282, Placebo = 284)		
Total no. of discontinuation due to adverse events	73 (25.9)	64 (22.5)
Discontinuation due to adverse events of interest		
Hypotension	3 (1.1)	0 (0.0)
Syncope or dizziness	0 (0.0)	0 (0.0)
Hypoglycemia	0 (0.0)	0 (0.0)
Anemia	2 (0.7)	3 (1.1)
Hyperkalaemia	26 (9.2)	15 (5.3)
Renal impairment	13 (4.6)	11 (3.9)
Acute renal failure	1 (0.4)	1 (0.4)